Regeneron Pharmaceuticals (REGN) Assets Average (2010 - 2026)

Regeneron Pharmaceuticals has reported Assets Average for 17 years, with the latest figure at $40.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 8.13% year-over-year to $40.7 billion; the trailing twelve-month figure through Mar 2026 stood at $40.7 billion (up 8.13% YoY), and the FY2025 full-year result was $39.2 billion, up 10.56% from the prior year.
• Assets Average for Q1 2026 stood at $40.7 billion, up from $40.4 billion in the prior quarter.
• The five-year high for Assets Average was $40.7 billion in Q1 2026, with the low at $25.9 billion in Q1 2022.
• Average Assets Average over 5 years is $33.6 billion, with a median of $33.7 billion recorded in 2024.
• Year-over-year, Assets Average surged 48.23% in 2022 and gained 6.61% in 2025.
• Tracing REGN's Assets Average over 5 years: stood at $28.4 billion in 2022, then grew by 14.68% to $32.6 billion in 2023, then rose by 15.26% to $37.6 billion in 2024, then advanced by 7.35% to $40.4 billion in 2025, then gained by 0.87% to $40.7 billion in 2026.
• The last three Assets Average figures came in at $40.7 billion (Q1 2026), $40.4 billion (Q4 2025), and $39.2 billion (Q3 2025), per Business Quant data.

Peer Comparison